DESTINY-PANTUMOUR04
← catalyst calendarNCT07124000 · readout in 589 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
100estimated
Sites
18
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-18 | actual | When the study began enrolling |
| Primary completion | 2028-03-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-03-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Adenocarcinoma (NOS)
- Anal Cancer
- Bladder Cancer
- Cervical Cancer
- Endometrial Cancer
- Esophageal Cancer
- Gall Bladder Cancer
- Gastrointestinal Stromal Tumour
- Head and Neck Cancer
- Liver Cancer
- Melanoma
- Mouth Cancer
- Nasopharangeal Cancer
- Neuroendocrine, Gastrointestinal Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer
- Renal Cell Carcinoma
- Salivary Gland Cancer
- Sarcoma
- Small Cell Lung Cancer
- Testicular Cancer
- Throat Cancer
- Thyroid Cancer
- Urethral Cancer
- Vaginal Cancer
- Vulvar Cancer
Intervention
- Drug: Trastuzumab deruxtecan — also filed as Enhertu
Primary outcomes
what the primary-completion date above is the date OFReal world response rate (rwRR)
measured Through study completion, up to 2.5 years after enrolment
Real world duration of response (rwDoR)
measured Through study completion, up to 2.5 years after enrolment
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed